Mechanistic Evaluation of Therapeutic Targets derived from Treatable Traits to Improve CNS Outcomes in People with HIV (R21/R33 Clinical Trial Not Allowed)
Agency
National Institutes of Health
Posted
Sep 30, 2026
Due Date
Oct 28, 2027
Description
<p>The purpose of this notice of funding opportunity (NOFO) is to identify modifiable mechanisms and therapeutic targets to address central nervous system (CNS) complications associated with human immunodeficiency virus (HIV). The initiative supports a phased research approach beginning with the identification of patient phenotypes characterized by convergent pathophysiological features, followed by the discovery and experimental validation of molecular mechanisms using innovative in-vitro and in-vivo models. The goal of this NOFO is to advance therapeutic target, and intervention discovery to address the multifactorial and heterogeneous nature of HIV-associated CNS dysfunction.</p>
AI Summary
Agency: National Institutes of Health
Details
- Notice ID
- 359657
- Solicitation Number
- RFA-MH-27-125
- Classification Code
- D
Want to track opportunities like this?
Sign up for Kontratar to get AI-powered opportunity matching, ranking, and alerts.
Get Started FreeRelated opportunities
- NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed)
National Institutes of Health
- CAPSTONE Centers for Multidisciplinary Research in Child Abuse and Neglect
National Institutes of Health
- Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource-Constrained Settings--Implementation Science Network (PATC3H-IN)
National Institutes of Health
- Discovery Gateway to Reproductive Health Innovation
National Institutes of Health
- National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
National Institutes of Health
- Coordinating Center for National Resource Network for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed)
National Institutes of Health
- Immune Tolerance Network (UM1 Clinical Trial Required)
National Institutes of Health
- Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)
National Institutes of Health